Navigation Links
Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
Date:5/13/2008

s is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the U.K. Phase II combination REOLYSIN(R)/paclitaxel and carboplatin clinical trial, and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the tolerability of REOLYSIN(R) outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN(R), uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) ... on the development of autologous cell therapies, today ... 30, 2015, corporate highlights, and near-term milestones.  The ... at www.sedar.com ,  www.edgar.com and ... expects to launch its RCS-01 treatment for aging ...
(Date:8/27/2015)... ... August 27, 2015 , ... Capital Edge Consulting ... business problems, is pleased to announce their ranking as one of the top 5000 ... the fastest-growing private companies across the nation. , “It is truly an honor to ...
(Date:8/27/2015)... 27, 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... regenerative medicine, today announced that executives from the company ... of September.  , Pedro Lichtinger ... Renshaw,s 17th Annual Global Investment Conference on Wednesday, September ... Regis Hotel in New York City ...
(Date:8/27/2015)... ... 2015 , ... Inc. Magazine released its annual list of the 5,000 fastest-growing ... growth for the three years through 2014. Being named to the Inc. 5000 list ... the country. , “We are thrilled to make the Inc. 5000 list for ...
Breaking Biology Technology:RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3
... 2011 BioSpecifics Technologies Corp. (NASDAQ: BSTC ... products marketed as XIAFLEX ® in the U.S. ... announced the appointment of  George Gould, Esq., to its ... an attorney, is Principal of George M. Gould, LLC, ...
... 2011  Janssen Biotech, Inc., one of the Janssen Pharmaceutical ... ), announced today that it has executed an agreement ... jointly develop and market the anti-cancer compound, PCI-32765.  A ... are ongoing across a panel of B-cell malignancy disorders, ...
... December 8, 2011 The Joint Management ... (ENPI CBC MED program) has informed Prof Nava ... they will award a contract of up to 2 ... and directed by Hadassah College, will be implemented in ...
Cached Biology Technology:BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors 2BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors 3BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors 4Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765 2Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765 3The European Union Signs Grant Contract to Fund a 2 Million Euro Biotechnology Research Project Led by Hadassah College Jerusalem 2
(Date:8/26/2015)... -- The report "Multi-Factor Authentication (MFA) Market by ... & Immigration, Government, Banking, Defense, Commercial Security, Consumer Electronics, ... by MarketsandMarkets, Multi-Factor Authentication Market is expected to reach ... of 17.7% between 2015 and 2020. ... through 169 P ages and in-depth ...
(Date:8/20/2015)... PLEASANTON, Calif. , Aug. 20, 2015 /PRNewswire/ ... focused on consumers that are active and healthy. ... used in the hospital environment to help improve ... released a video from the Wearable Technologies ... MD discussed new applications for wearables in healthcare.    ...
(Date:8/18/2015)... 18, 2015  Navitas today announced that ... the Submission Content Management webinar scheduled on ... forum. Dedicated to the Implementation of Regulatory Submission ... for industry, vendors, health authorities, consultants and ... towards a standard method of implementing electronic ...
Breaking Biology News(10 mins):Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3
... researchers has identified 11 new genes that offer ... in Alzheimer,s disease. The highly collaborative effort involved ... genetic analysis yet conducted in Alzheimer,s researchto discover ... disease, the most common form of the disorder. ...
... Cell culture systems for specific neural cell types ... function. Purifying and Culturing Neural Cells: A ... cell populations from rodent tissues and culturing them ... The contributors describe in detail how to dissect ...
... penetrating icy blue glare of car headlights and could be fundamental ... the heart of diodes. Not the kind you might find in ... gallium nitride or InGaN. This alloy forms the light emitting region ... diodes (LDs) in the blue-UV range. Research into making ...
Cached Biology News:NIH-supported study identifies 11 new Alzheimer's disease risk genes 2NIH-supported study identifies 11 new Alzheimer's disease risk genes 3ASU, Georgia Tech create breakthrough for solar cell efficiency 2
...
...
Kit for testing the ability of a compound to simulate lipolysis in cultured human adipocytes. Kit contains controls, buffers and reagents for detecting glycerol and non-esterified free fatty acids. A...
The strip cap tool is a used for properly seating 8- and 12-cap strips in microplates or strip tubes. A grooved channel on one side is designed to seat domed caps, while the flat edge on the opposite...
Biology Products: